[The P phenomenon in progressive chronic polyarthritis (pcP) and collagen diseases].
D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D001379:Azathioprine / Q000627:therapeutic use; D002097:C-Reactive Protein; D002908:Chronic Disease; D003095:Collagen Diseases / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004983:Ethanolamines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011033:Podophyllin / Q000627:therapeutic use; D011035:Podophyllum; D051381:Rats; D012217:Rheumatoid Factor; D014228:Triaziquone / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000502:physiology*
D000970:Antineoplastic Agents; D004983:Ethanolamines; D014662:Vasoconstrictor Agents; D003520:Cyclophosphamide; D011033:Podophyllin; D002097:C-Reactive Protein; D012217:Rheumatoid Factor; D014228:Triaziquone; D001379:Azathioprine
Das P-Phänomen bei progressiv chronischer Polyarthritis (pcP) und Kollagenosen.